Lantheus Corp (LNTH) Forward Price-to-Revenue Multiple

Lantheus Corp (LNTH) - corporate logo

A stable staff of radiologists and the motivation of R&D personnel create a foundation for the growth of Lantheus Holdings, Inc. (LNTH). However, reliance on imports from Asia and Europe leaves raw material logistics vulnerable to sanctions. The forward P/S metric captures these risks, where the parameter value equals 2.60. Meanwhile, global conflicts and the short shelf life of drugs limit the company's expansion into international markets.

Lantheus - LNTH Forward Price to Sales (period 07/04/2022 - 11/17/2026)

Lantheus Holdings, Inc. (LNTH) - metric breakdowns and financial figures

- market price and analyst price targets:
Fundamental company valuation:Lantheus Corp LNTH
Original product of Lantheus Corp

Lantheus Holdings, Inc. (LNTH) controls a monopoly segment of radiopharmaceuticals, where the unique logistics of Pylarify and FDA protection guarantee exceptional clinic loyalty. This forward price-to-sales ratio chart correlates the company's market value with expected sales, allowing investors to conduct a real-time assessment of business stability and promptly identify either an undervalued asset or rising liquidity risks.